Chernov et al., 2023 - Google Patents
Phase I trial of [99mTc] Tc-maSSS-PEG2-RM26, a bombesin analogue antagonistic to gastrin-releasing peptide receptors (GRPRs), for SPECT imaging of GRPR …Chernov et al., 2023
View HTML- Document ID
- 5456914405104996870
- Author
- Chernov V
- Rybina A
- Zelchan R
- Medvedeva A
- Bragina O
- Lushnikova N
- Doroshenko A
- Usynin E
- Tashireva L
- Vtorushin S
- Abouzayed A
- Rinne S
- Sörensen J
- Tolmachev V
- Orlova A
- Publication year
- Publication venue
- Cancers
External Links
Snippet
Simple Summary Prostate and breast cancers are the most common malignancies. Accurate diagnosis and staging of diseases are important for the prognosis and determination of treatment tactics. The gastrin-releasing peptide receptor is overexpressed in over 80% of …
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/0493—Steroids, e.g. cholesterol, testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q50/00—Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
- G06Q50/10—Services
- G06Q50/22—Health care, e.g. hospitals; Social work
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Lenzo et al. | Review of gallium-68 PSMA PET/CT imaging in the management of prostate cancer | |
Vahidfar et al. | Theranostic advances in breast cancer in nuclear medicine | |
Awenat et al. | Diagnostic role of 18F-PSMA-1007 PET/CT in prostate cancer staging: a systematic review | |
Chernov et al. | Phase I trial of [99mTc] Tc-maSSS-PEG2-RM26, a bombesin analogue antagonistic to gastrin-releasing peptide receptors (GRPRs), for SPECT imaging of GRPR expression in malignant tumors | |
Kaloudi et al. | NeoBOMB1, a GRPR-antagonist for breast cancer theragnostics: First results of a preclinical study with [67Ga] NeoBOMB1 in T-47D cells and tumor-bearing mice | |
Plichta et al. | Prostate-specific membrane antigen (PSMA) theranostics for treatment of oligometastatic prostate cancer | |
Hadebe et al. | The role of PET/CT in breast cancer | |
Ma et al. | PET/CT for predicting occult lymph node metastasis in gastric cancer | |
Kaewput et al. | Update of PSMA theranostics in prostate cancer: current applications and future trends | |
Nock et al. | [99mTc] Tc-DB15 in GRPR-targeted tumor imaging with SPECT: from preclinical evaluation to the first clinical outcomes | |
Wong et al. | 64Cu-SAR-bombesin PET-CT imaging in the staging of estrogen/progesterone receptor positive, HER2 negative metastatic breast cancer patients: safety, dosimetry and feasibility in a Phase I trial | |
Vahidfar et al. | A review of nuclear medicine approaches in the diagnosis and the treatment of gynecological malignancies | |
Tan et al. | PSMA PET imaging and therapy in adenoid cystic carcinoma and other salivary gland cancers: a systematic review | |
Lundmark et al. | Preclinical characterisation of PSMA/GRPR-targeting heterodimer [68Ga] Ga-BQ7812 for PET diagnostic imaging of prostate cancer: A step towards clinical translation | |
Abouzayed et al. | Preclinical evaluation of 99mTc-labeled GRPR antagonists maSSS/SES-PEG2-RM26 for imaging of prostate cancer | |
Farr et al. | Imaging modalities for early detection of pancreatic cancer: Current state and future research opportunities | |
Klain et al. | Advances in functional imaging of differentiated thyroid cancer | |
Taralli et al. | PET/CT with fibroblast activation protein inhibitors in breast cancer: diagnostic and theranostic application—a literature review | |
Gruber et al. | Imaging properties and tumor targeting of 68ga-neobomb1, a gastrin-releasing peptide receptor antagonist, in gist patients | |
Bragina et al. | Direct intra-patient comparison of scaffold protein-based tracers,[99mTc] Tc-ADAPT6 and [99mTc] Tc-(HE) 3-G3, for imaging of HER2-Positive breast cancer | |
Baun et al. | Preclinical evaluation of the copper-64 labeled GRPR-antagonist RM26 in comparison with the cobalt-55 labeled counterpart for PET-imaging of prostate cancer | |
Ferrari et al. | [18F] fluciclovine vs.[18F] fluorocholine positron emission tomography/computed tomography: a head-to-head comparison for early detection of biochemical recurrence in prostate cancer patients | |
Ćwikła et al. | Initial experience of clinical use of [99mTc] Tc-PSMA-T4 in patients with prostate cancer. A pilot study | |
Jetty et al. | Prostate Cancer—PET Imaging Update | |
Coria-Domínguez et al. | [99mTc] Tc-iFAP radioligand for SPECT/CT imaging of the tumor microenvironment: kinetics, radiation dosimetry, and imaging in patients |